Skip to content

Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort

Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02356497
Acronym
PRESENT
Enrollment
2500
Registered
2015-02-05
Start date
2013-06-01
Completion date
2035-12-01
Last updated
2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone Metastases

Keywords

Bone metastases, Metastatic bone disease, Multi-trial facility

Brief summary

Bone metastases are frequent distant manifestations of cancer, with pain as a common and devastating consequence. The primary treatment for painful bone metastases, external beam radiation therapy, is moderately effective: about 60% of patients who undergo conventional radiotherapy experience (partial) pain relief. Several factors associated with treatment failure have been identified, but no attempts have been made to collapse these factors into a clinically useful prediction tool to predict treatment response. In addition, to aid in therapy selection based on expected survival time, development of survival models is essential. Finally, we need innovative treatments as alternatives or additive to standard treatment options to improve quality of life (QoL). For these reasons, we set up the PRESENT cohort study, recruiting patients at the departments of radiation oncology and orthopedic surgery. We aim to provide detailed information about clinical data, create an infrastructure for efficient, fast and pragmatic evaluation and implementation of innovative interventions, as well as development of accurate new prediction tools.

Detailed description

The PRESENT cohort is set up according to the 'cohort multiple Randomised Controlled Trial' design. The basis of this design is a prospective cohort of patients with bone metastases, receiving care as usual, who give informed consent for cohort participation. At the UMC Utrecht, patients are furthermore asked for informed consent to be randomized in future RCTs conducted within the cohort. Patients are informed that they will be offered the experimental intervention if they are randomly selected. They are also informed that they otherwise might serve as controls without being notified and that their data can be used in a trial context. For each patient in the cohort, clinical and patient-reported outcomes are captured at baseline and at regular intervals during follow-up. Within this cohort, multiple RCTs can be conducted. For this purpose, eligible patients who have provided the consent required for them to participate in an RCT within the cohort are identified. From this subcohort, a random selection of patients will be invited to undergo the experimental intervention. Eligible participants who were not randomly selected receive standard care, are not informed about the experimental intervention and serve as controls. Outcomes in this control group are compared with the outcomes of those who were offered the experimental intervention, in order to estimate the effect of the experimental intervention versus usual care. Within the cohort, the same process can be repeated for trials of other interventions.

Interventions

None listed

Sponsors

UMC Utrecht
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologic proof of malignancy; * Radiographic or histologic proof of metastatic bone disease; * Undergoing radiotherapy; * Age \> 18 years; * Informed consent - at least - for use of routinely collected clinical data.

Exclusion criteria

* Mentally incompetent patients; * Life expectancy \< 1 week indicated by the treating physician.

Design outcomes

Primary

MeasureTime frame
Pain responseat 2, 4, 6, 8 weeks, 3 and 6 months, then every 6 months

Secondary

MeasureTime frameDescription
Health-related Quality of Lifeat 2, 4, 6, 8 weeks and 3 months
Toxicity according to CTCAE version 4up to 3 monthsGrade 3 and 4 side effects occurring during or up to 3 months after radiotherapy will be registered according to the Common Terminology Criteria for Adverse Events (CTCAE version 4). The following side effects will be registered: Nausea; Vomiting; Diarrhoea; Pain flare.
Readmissionup to 3 yearsReintervention (reirradiation, surgery, other); Development of neurological symptoms; Development of pathologic fracture
Survivalup to 3 yearsSurvival of participating patients will be recorded using the follow up questionnaires (returned by family members) or are derived from the Municipal Personal Records Database (in Dutch: Gemeentelijke Basisadministratie, GBA).

Countries

Netherlands

Contacts

CONTACTRoxanne Gal, PhD
r.gal@umcutrecht.nl
PRINCIPAL_INVESTIGATORHelena M. Verkooijen, MD, PhD

UMC Utrecht

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026